Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug

Executive Summary

As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.

You may also be interested in...

Nanobody Specialist Ablynx Bags Global IL-6R Deal With AbbVie

Ablynx stands to get $840 million and double-digit royalties under a global license deal with AbbVie to develop and commercialize the Belgian group’s anti-IL-6R candidate ALX-0061 to treat inflammatory diseases. The transaction brings a big boost to the biotech’s prospects.

Abbott Vaults Into Oral HCV Race; Near-Term Focus Is Humira, Split

The pharma did not offer much detail on plans to split into two publicly traded companies during its quarterly call, but did shed some light on its HCV pipeline one day ahead of EASL.

Abbott Spin-Off AbbVie To Remain Close To Its Roots

Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts